Acadia Pharmaceuticals Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.
No news available
Limited Time
Get premium stock ratings, research, analyst insights, and portfolio tools with a limited-time discount.
25% off Seeking Alpha Premium through July 7.
Claim 25% discountSponsored partner offer: The 25% Seeking Alpha Premium discount is available for a limited time. Terms apply.